These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24643055)

  • 1. Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial.
    Tarhan F; Çelik O; Tosun Ç; Faydacı G; Eryıldırım B
    Urol Int; 2014; 93(1):17-21. PubMed ID: 24643055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
    Lee YC; Juan YS; Liu CC; Bao BY; Wang CJ; Wu WJ; Huang CN; Huang SP
    BJU Int; 2016 Aug; 118(2):313-9. PubMed ID: 26940040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Comparison of the Efficacy of Isosorbide Mononitrate and Doxazosin in the Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: A Randomized Clinical Trial.
    Kaplan SA
    J Urol; 2015 Dec; 194(6):1702. PubMed ID: 26582690
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
    Chung MS; Lee SH; Park KK; Yoo SJ; Chung BH
    Int J Clin Pract; 2011 Nov; 65(11):1193-9. PubMed ID: 21995695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
    Salah Azab S; Elsheikh MG
    Aging Male; 2015 Jun; 18(2):89-92. PubMed ID: 25295872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes.
    Lee HN; Kim TH; Lee SJ; Cho WY; Shim BS
    Int Braz J Urol; 2014; 40(3):356-66. PubMed ID: 25010301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effect of α-blockers and antimuscarinics in male lower urinary tract symptoms based on the International Prostate Symptom Score subscore ratio.
    Liao CH; Lin VC; Chung SD; Kuo HC
    Int J Clin Pract; 2012 Feb; 66(2):139-45. PubMed ID: 22257039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia.
    Jiang YH; Liao CH; Kuo HC
    Int J Clin Pract; 2014 Sep; 68(9):1081-6. PubMed ID: 24673775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
    Lin VC; Liao CH; Kuo HC
    Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
    Samli MM; Dincel C
    Urol Int; 2004; 73(2):125-9. PubMed ID: 15331896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of metabolic syndrome on the responsiveness to α1-blocker in men with BPH/LUTS.
    Lee YC; Liu CC; Juan YS; Wu WJ; Li WM; Yeh HC; Wang CJ; Huang CN; Huang CH; Huang SP
    Int J Clin Pract; 2013 Apr; 67(4):356-62. PubMed ID: 23409734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Doxazosin on Alpha 1-Adrenergic Receptors in Prostates with Benign Prostatic Hyperplasia.
    Lee HN; Lee KS; Lee SY; Shim BS; Lee YS; Hong JH; Lim BH; Lee HM
    Low Urin Tract Symptoms; 2013 May; 5(2):82-9. PubMed ID: 26663375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.
    El-Tatawy H; Gameel T; El-enen MA; Hagras A; Mousa A; El-Bahnasy AH; Raheem AA; Abu-dewan K
    Arch Ital Urol Androl; 2015 Sep; 87(3):238-42. PubMed ID: 26428648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.